CN104968353B - 吉西他滨前药及其用途 - Google Patents

吉西他滨前药及其用途 Download PDF

Info

Publication number
CN104968353B
CN104968353B CN201380059144.8A CN201380059144A CN104968353B CN 104968353 B CN104968353 B CN 104968353B CN 201380059144 A CN201380059144 A CN 201380059144A CN 104968353 B CN104968353 B CN 104968353B
Authority
CN
China
Prior art keywords
oxo
anilino
alkyl
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380059144.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104968353A (zh
Inventor
L·I·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boyan Pharmaceutical Development Co ltd
Original Assignee
Boyan Pharmaceutical Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boyan Pharmaceutical Development Co ltd filed Critical Boyan Pharmaceutical Development Co ltd
Publication of CN104968353A publication Critical patent/CN104968353A/zh
Application granted granted Critical
Publication of CN104968353B publication Critical patent/CN104968353B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN201380059144.8A 2012-11-13 2013-11-12 吉西他滨前药及其用途 Active CN104968353B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725643P 2012-11-13 2012-11-13
US61/725,643 2012-11-13
PCT/US2013/069640 WO2014078295A1 (en) 2012-11-13 2013-11-12 Gemcitabine prodrugs and uses thereof

Publications (2)

Publication Number Publication Date
CN104968353A CN104968353A (zh) 2015-10-07
CN104968353B true CN104968353B (zh) 2017-12-22

Family

ID=50681903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380059144.8A Active CN104968353B (zh) 2012-11-13 2013-11-12 吉西他滨前药及其用途

Country Status (10)

Country Link
US (3) US8956613B2 (enExample)
EP (1) EP2919790B1 (enExample)
JP (1) JP6420247B2 (enExample)
KR (1) KR20150082606A (enExample)
CN (1) CN104968353B (enExample)
AU (1) AU2013345007B2 (enExample)
BR (1) BR112015010941A2 (enExample)
CA (1) CA2891124A1 (enExample)
SG (1) SG11201503773SA (enExample)
WO (1) WO2014078295A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010941A2 (pt) 2012-11-13 2017-07-11 Boyen Therapeutics Inc pró-fármacos de gemcitabina e suas utilizações
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016078397A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物及其应用
WO2016078163A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
WO2016078399A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
ITUB20159671A1 (it) * 2015-12-22 2017-06-22 Maurizio Ceruti Carbammati lipidici di farmaci antitumorali
PL3393478T3 (pl) * 2015-12-23 2020-07-13 NuCana plc Terapia skojarzona
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
CN108329371B (zh) * 2018-03-06 2021-04-09 沈阳药科大学 白蛋白结合型吉西他滨前药及其合成和应用
AU2019258590B2 (en) * 2018-04-26 2022-09-08 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
GB201906214D0 (en) 2019-05-02 2019-06-19 Econic Tech Ltd A polyol block copolymer, compositions and processes therefor
GB201906210D0 (en) 2019-05-02 2019-06-19 Econic Tech Limited A polyol block copolymer, compositions and processes therefor
CN114011581B (zh) * 2021-11-09 2023-03-24 昆明理工大学 一种弱酸性条件下铜硫分离的抑制剂制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0986570B1 (en) * 1997-01-24 2003-04-02 ConPharma AS Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814438A (en) 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
GB2321454A (en) 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2006030217A2 (en) 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AT502221A1 (de) 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
KR101108407B1 (ko) 2006-06-21 2012-01-30 일라이 릴리 앤드 캄파니 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
KR101705077B1 (ko) 2008-10-07 2017-02-09 렉산 파마슈티컬스, 인코포레이티드 Ｈｐｍａ-도세탁셀 또는 젬시타빈 컨쥬게이트 및 이의 용도
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
EP2448408A4 (en) * 2009-07-02 2015-06-03 Kempharm Inc CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
WO2011062503A1 (en) 2009-11-20 2011-05-26 Clavis Pharma As Parenteral formulations of gemcitabine derivatives
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012098557A1 (en) 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
WO2013019945A2 (en) 2011-08-02 2013-02-07 Clovis Oncology, Inc.. Method for selection of chemotherapeutic agents for adenocarcinoma cancer
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
BR112015010941A2 (pt) 2012-11-13 2017-07-11 Boyen Therapeutics Inc pró-fármacos de gemcitabina e suas utilizações
CN103130854A (zh) 2013-01-31 2013-06-05 华东师范大学 维生素e琥珀酸酯化吉西他滨前药及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0986570B1 (en) * 1997-01-24 2003-04-02 ConPharma AS Gemcitabine derivatives
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Amino Acid Ester Prodrugs of the Anticancer Agent;Xueqin Song等;《Molecular Pharmaceutics》;20050316;第2卷(第2期);1543－8384 *

Also Published As

Publication number Publication date
CA2891124A1 (en) 2014-05-22
EP2919790A4 (en) 2016-04-06
WO2014078295A8 (en) 2015-05-21
EP2919790B1 (en) 2018-04-04
AU2013345007A1 (en) 2015-05-21
JP2016503414A (ja) 2016-02-04
KR20150082606A (ko) 2015-07-15
CN104968353A (zh) 2015-10-07
JP6420247B2 (ja) 2018-11-07
US8956613B2 (en) 2015-02-17
AU2013345007B2 (en) 2018-08-30
WO2014078295A1 (en) 2014-05-22
US9540410B2 (en) 2017-01-10
EP2919790A1 (en) 2015-09-23
US20150132298A1 (en) 2015-05-14
BR112015010941A2 (pt) 2017-07-11
US20170107245A1 (en) 2017-04-20
SG11201503773SA (en) 2015-06-29
US20140134160A1 (en) 2014-05-15
US9890189B2 (en) 2018-02-13

Similar Documents

Publication Publication Date Title
CN104968353B (zh) 吉西他滨前药及其用途
JP7414525B2 (ja) クロファラビンのプロドラッグ
EP4209483A1 (en) Prodrug modulators of the integrated stress pathway
CN102421429B (zh) 癌症治疗用选择性ep4受体拮抗物质
US11918582B2 (en) Pyrazole pyrimidine compounds and uses thereof
US9862693B2 (en) Compounds and methods of treating cancer
US20220274964A1 (en) 5-bromo-indirubins
US11701377B2 (en) Methods for treating cancers by prodrugs of clofarabine
CA3042671C (en) Prodrugs of clofarabine
CN115461054A (zh) 延伸因子1-α抑制剂及其用途
WO2020028525A1 (en) Sumo inhibitor compounds and uses thereof
US10646479B2 (en) Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer
WO2021154870A1 (en) Igf2bp2 inhibitors and uses thereof
HK1220197B (en) 5-bromo-indirubins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Taipei City, Taiwan, China

Applicant after: Bo Yan pharmaceutical development Limited by Share Ltd

Address before: Taipei City, Taiwan, China

Applicant before: BOYEN THERAPEUTICS INC.

COR Change of bibliographic data
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant